The Experts below are selected from a list of 30 Experts worldwide ranked by ideXlab platform
Maryse Paquet - One of the best experts on this subject based on the ideXlab platform.
-
REVIEW Systematic Review of Systemic Treatments for Tinea Versicolor and Evidence-Based Dosing Regimen Recommendations
2016Co-Authors: Aditya K Gupta, Danielle Lane, Maryse PaquetAbstract:Background: Extensive or recurrent tinea versicolor (TV) can be treated with systemic antifungal therapies, but no dosing regimens have been approved for this indication. Objective: To provide evidence-based recommendations for dosing regimens. Methods: A systematic literature searchwas performed to identify trials reportingmycologic cure. All trialswere included and assessed for quality. Correlation and statistical analyses were used to evaluate the effects of different dosing regimen parameters on efficacy. Results: Fifty-seven trials investigating itraconazole, ketoconazole, fluconazole, and Pramiconazole were included. Cumulative dose, treatment duration, and daily/weekly concentrations were shown to significantly influence mycologic cure rates for ketoconazole and Pramiconazole but not for itraconazole and fluconazole. Conclusion: Based on the efficacy evidence and potential safety concerns, this review supports the following dosing regimens: 200 mg/d for 5 or 7 days of itraconazole, 300 mg/wk for 2 weeks of fluconazole, and 200 mg/d for 2 days of Pramiconazole. Contexte: Le pityriasis versicolor étendu ou récidivant peut se traiter par des antifongiques a ̀ action générale, mais aucun régime posologique n’a éte ́ approuve ́ pour cette indication. Objectif: L’étude visait a ̀ formuler des recommandations sur la posologie, fondées sur des données probantes. Méthode: Nous avons procéde ́ a ̀ un examen méthodique de la documentation a ̀ la recherche d’essais faisant état de la guérison mycologique. Tous les essais ainsi relevés ont éte ́ inclus dans l’étude et soumis a ̀ une évaluation de la qualité. L’effet, sur l’efficacité
-
REVIEW Systematic Review of Systemic Treatments for Tinea
2016Co-Authors: Tinea Versicolor, Maryse Paquet, Aditya K Gupta, Danielle Lane, Evidence-based Dosing, Aditya Gupta, Evidence-based Dosing RegimenAbstract:Background: Extensive or recurrent tinea versicolor (TV) can be treated with systemic antifungal therapies, but no dosing regimens have been approved for this indication. Objective: To provide evidence-based recommendations for dosing regimens. Methods: A systematic literature searchwas performed to identify trials reportingmycologic cure. All trialswere included and assessed for quality. Correlation and statistical analyses were used to evaluate the effects of different dosing regimen parameters on efficacy. Results: Fifty-seven trials investigating itraconazole, ketoconazole, fluconazole, and Pramiconazole were included. Cumulative dose, treatment duration, and daily/weekly concentrations were shown to significantly influence mycologic cure rates for ketoconazole and Pramiconazole but not for itraconazole and fluconazole. Conclusion: Based on the efficacy evidence and potential safety concerns, this review supports the following dosing regimens: 200 mg/d for 5 or 7 days of itraconazole, 300 mg/wk for 2 weeks of fluconazole, and 200 mg/d for 2 days of Pramiconazole. Contexte: Le pityriasis versicolor étendu ou récidivant peut se traiter par des antifongiques a ̀ action générale, mais aucun régime posologique n’a éte ́ approuve ́ pour cette indication. Objectif: L’étude visait a ̀ formuler des recommandations sur la posologie, fondées sur des données probantes. Méthode: Nous avons procéde ́ a ̀ un examen méthodique de la documentation a ̀ la recherche d’essais faisant état de la guériso
-
systematic review of systemic treatments for tinea versicolor and evidence based dosing regimen recommendations
Journal of Cutaneous Medicine and Surgery, 2014Co-Authors: Aditya K Gupta, Danielle Lane, Maryse PaquetAbstract:Background:Extensive or recurrent tinea versicolor (TV) can be treated with systemic antifungal therapies, but no dosing regimens have been approved for this indication.Objective:To provide evidence-based recommendations for dosing regimens.Methods:A systematic literature search was performed to identify trials reporting mycologic cure. All trials were included and assessed for quality. Correlation and statistical analyses were used to evaluate the effects of different dosing regimen parameters on efficacy.Results:Fifty-seven trials investigating itraconazole, ketoconazole, fluconazole, and Pramiconazole were included. Cumulative dose, treatment duration, and daily/weekly concentrations were shown to significantly influence mycologic cure rates for ketoconazole and Pramiconazole but not for itraconazole and fluconazole.Conclusion:Based on the efficacy evidence and potential safety concerns, this review supports the following dosing regimens: 200 mg/d for 5 or 7 days of itraconazole, 300 mg/wk for 2 weeks ...
-
systematic review of oral treatments for seborrheic dermatitis
Journal of The European Academy of Dermatology and Venereology, 2014Co-Authors: M Richardson, Maryse PaquetAbstract:Seborrheic dermatitis (SD) is normally treated with topical corticosteroids and antifungals. Oral therapies can be prescribed in severe or unresponsive cases. This review aims to assess the quantity and quality of published reports on oral therapies for SD. MEDLINE and Embase databases and the reference listings of publications were searched for any publication using oral treatment for SD. The quality of the included publications was assessed using a modified 27 item checklist by Downs and Black. Twenty-one publications (randomized controlled trials, open trials and case reports) covering eight oral therapies (itraconazole, terbinafine, fluconazole, ketoconazole, Pramiconazole, prednisone, isotretinoin and homeopathic mineral therapy) were identified. Most of the publications investigated oral antifungals and the quality of the evidence was generally low. The clinical efficacy outcome reported varied considerably between the studies, preventing statistical analysis and direct comparison between treatments. However, ketoconazole therapy was associated with more relapses compared with other treatments. Itraconazole dosing regimen for SD was generally 200 mg/day for the first week of the month followed by 200 mg/day for the first 2 days for 2–11 months. Terbinafine was prescribed at 250 mg/day either as a continuous (4–6 weeks) or as an intermittent regimen (12 days per month) for 3 months. Fluconazole has administered daily (50 mg/day for 2 weeks) or weekly (200–300 mg) for 2–4 weeks. Ketoconazole dosing regimen was 200 mg daily for 4 weeks. Finally, a single 200 mg dose of Pramiconazole was administered to patients. This review also highlights key areas for consideration when designing future studies.
Marcel Borgers - One of the best experts on this subject based on the ideXlab platform.
-
the effect of antifungal treatment on the vaginal flora of women with vulvo vaginal yeast infection with or without bacterial vaginosis
European Journal of Clinical Microbiology & Infectious Diseases, 2011Co-Authors: Gilbert G G Donders, Gert Bellen, Jannie Ausma, L Verguts, J Vaneldere, Piet Hinoul, Marcel Borgers, D JanssensAbstract:Antibacterial therapy may enhance the risk of symptomatic vulvo-vaginal candidosis in susceptible women. We addressed the question whether oral antifungal treatment for vulvo-vaginal candidosis also influences the bacterial vaginal microflora. One hundred and forty-two patients with a culture-proven acute episode of recurrent vulvo-vaginal candidosis (RVC) were treated with fuconazole according to the ReCiDiF regimen (induction dose of 600 mg orally per week followed by 200 mg per week) or with a single dose of 200 mg Pramiconazole, a new potent oral triazole. At inclusion, 1 week and 1 month after the end of antifungal treatment, the bacterial microflora was assessed by microscopy of vaginal fluid to detect lactobacillary grades and bacterial vaginosis (BV). The presence of BV was studied in these patients with vulvo-vaginal candidosis after treatment with antifungal medication. At the start of oral antifungal treatment, 6.3% of women with Candida were co-infected with BV. Of the BV-negative women, 10 out of 133 (8%) developed BV after 1 week and after 1 month 8 of them (7%) were still BV-positive. Although no patients received antibacterial treatment at any moment of the study, 6 out of 9 (66%) of the women with Candida and BV at inclusion no longer had BV 1 week after antifungal treatment and 6 out of 7 (86%) lacked BV after 1 month. Treatment with antifungals may have a beneficial effect on women with concurrent BV, but does not prevent BV from occurring in BV-negative women with Candida vaginitis.
-
a pilot study on seborrheic dermatitis using Pramiconazole as a potent oral anti malassezia agent
Dermatology, 2007Co-Authors: Gerald Pierard, Jannie Ausma, Marcel Borgers, Frederique Henry, Valerie Vroome, Luc Wouters, Geert Cauwenbergh, Claudine PierardfranchimontAbstract:Background: Seborrheic dermatitis is considered to be a Malassezia -driven disease. Little objective information is available so far from biometrological quantitat
Jannie Ausma - One of the best experts on this subject based on the ideXlab platform.
-
the effect of antifungal treatment on the vaginal flora of women with vulvo vaginal yeast infection with or without bacterial vaginosis
European Journal of Clinical Microbiology & Infectious Diseases, 2011Co-Authors: Gilbert G G Donders, Gert Bellen, Jannie Ausma, L Verguts, J Vaneldere, Piet Hinoul, Marcel Borgers, D JanssensAbstract:Antibacterial therapy may enhance the risk of symptomatic vulvo-vaginal candidosis in susceptible women. We addressed the question whether oral antifungal treatment for vulvo-vaginal candidosis also influences the bacterial vaginal microflora. One hundred and forty-two patients with a culture-proven acute episode of recurrent vulvo-vaginal candidosis (RVC) were treated with fuconazole according to the ReCiDiF regimen (induction dose of 600 mg orally per week followed by 200 mg per week) or with a single dose of 200 mg Pramiconazole, a new potent oral triazole. At inclusion, 1 week and 1 month after the end of antifungal treatment, the bacterial microflora was assessed by microscopy of vaginal fluid to detect lactobacillary grades and bacterial vaginosis (BV). The presence of BV was studied in these patients with vulvo-vaginal candidosis after treatment with antifungal medication. At the start of oral antifungal treatment, 6.3% of women with Candida were co-infected with BV. Of the BV-negative women, 10 out of 133 (8%) developed BV after 1 week and after 1 month 8 of them (7%) were still BV-positive. Although no patients received antibacterial treatment at any moment of the study, 6 out of 9 (66%) of the women with Candida and BV at inclusion no longer had BV 1 week after antifungal treatment and 6 out of 7 (86%) lacked BV after 1 month. Treatment with antifungals may have a beneficial effect on women with concurrent BV, but does not prevent BV from occurring in BV-negative women with Candida vaginitis.
-
a pilot study on seborrheic dermatitis using Pramiconazole as a potent oral anti malassezia agent
Dermatology, 2007Co-Authors: Gerald Pierard, Jannie Ausma, Marcel Borgers, Frederique Henry, Valerie Vroome, Luc Wouters, Geert Cauwenbergh, Claudine PierardfranchimontAbstract:Background: Seborrheic dermatitis is considered to be a Malassezia -driven disease. Little objective information is available so far from biometrological quantitat
D Janssens - One of the best experts on this subject based on the ideXlab platform.
-
the effect of antifungal treatment on the vaginal flora of women with vulvo vaginal yeast infection with or without bacterial vaginosis
European Journal of Clinical Microbiology & Infectious Diseases, 2011Co-Authors: Gilbert G G Donders, Gert Bellen, Jannie Ausma, L Verguts, J Vaneldere, Piet Hinoul, Marcel Borgers, D JanssensAbstract:Antibacterial therapy may enhance the risk of symptomatic vulvo-vaginal candidosis in susceptible women. We addressed the question whether oral antifungal treatment for vulvo-vaginal candidosis also influences the bacterial vaginal microflora. One hundred and forty-two patients with a culture-proven acute episode of recurrent vulvo-vaginal candidosis (RVC) were treated with fuconazole according to the ReCiDiF regimen (induction dose of 600 mg orally per week followed by 200 mg per week) or with a single dose of 200 mg Pramiconazole, a new potent oral triazole. At inclusion, 1 week and 1 month after the end of antifungal treatment, the bacterial microflora was assessed by microscopy of vaginal fluid to detect lactobacillary grades and bacterial vaginosis (BV). The presence of BV was studied in these patients with vulvo-vaginal candidosis after treatment with antifungal medication. At the start of oral antifungal treatment, 6.3% of women with Candida were co-infected with BV. Of the BV-negative women, 10 out of 133 (8%) developed BV after 1 week and after 1 month 8 of them (7%) were still BV-positive. Although no patients received antibacterial treatment at any moment of the study, 6 out of 9 (66%) of the women with Candida and BV at inclusion no longer had BV 1 week after antifungal treatment and 6 out of 7 (86%) lacked BV after 1 month. Treatment with antifungals may have a beneficial effect on women with concurrent BV, but does not prevent BV from occurring in BV-negative women with Candida vaginitis.
Aditya K Gupta - One of the best experts on this subject based on the ideXlab platform.
-
REVIEW Systematic Review of Systemic Treatments for Tinea Versicolor and Evidence-Based Dosing Regimen Recommendations
2016Co-Authors: Aditya K Gupta, Danielle Lane, Maryse PaquetAbstract:Background: Extensive or recurrent tinea versicolor (TV) can be treated with systemic antifungal therapies, but no dosing regimens have been approved for this indication. Objective: To provide evidence-based recommendations for dosing regimens. Methods: A systematic literature searchwas performed to identify trials reportingmycologic cure. All trialswere included and assessed for quality. Correlation and statistical analyses were used to evaluate the effects of different dosing regimen parameters on efficacy. Results: Fifty-seven trials investigating itraconazole, ketoconazole, fluconazole, and Pramiconazole were included. Cumulative dose, treatment duration, and daily/weekly concentrations were shown to significantly influence mycologic cure rates for ketoconazole and Pramiconazole but not for itraconazole and fluconazole. Conclusion: Based on the efficacy evidence and potential safety concerns, this review supports the following dosing regimens: 200 mg/d for 5 or 7 days of itraconazole, 300 mg/wk for 2 weeks of fluconazole, and 200 mg/d for 2 days of Pramiconazole. Contexte: Le pityriasis versicolor étendu ou récidivant peut se traiter par des antifongiques a ̀ action générale, mais aucun régime posologique n’a éte ́ approuve ́ pour cette indication. Objectif: L’étude visait a ̀ formuler des recommandations sur la posologie, fondées sur des données probantes. Méthode: Nous avons procéde ́ a ̀ un examen méthodique de la documentation a ̀ la recherche d’essais faisant état de la guérison mycologique. Tous les essais ainsi relevés ont éte ́ inclus dans l’étude et soumis a ̀ une évaluation de la qualité. L’effet, sur l’efficacité
-
REVIEW Systematic Review of Systemic Treatments for Tinea
2016Co-Authors: Tinea Versicolor, Maryse Paquet, Aditya K Gupta, Danielle Lane, Evidence-based Dosing, Aditya Gupta, Evidence-based Dosing RegimenAbstract:Background: Extensive or recurrent tinea versicolor (TV) can be treated with systemic antifungal therapies, but no dosing regimens have been approved for this indication. Objective: To provide evidence-based recommendations for dosing regimens. Methods: A systematic literature searchwas performed to identify trials reportingmycologic cure. All trialswere included and assessed for quality. Correlation and statistical analyses were used to evaluate the effects of different dosing regimen parameters on efficacy. Results: Fifty-seven trials investigating itraconazole, ketoconazole, fluconazole, and Pramiconazole were included. Cumulative dose, treatment duration, and daily/weekly concentrations were shown to significantly influence mycologic cure rates for ketoconazole and Pramiconazole but not for itraconazole and fluconazole. Conclusion: Based on the efficacy evidence and potential safety concerns, this review supports the following dosing regimens: 200 mg/d for 5 or 7 days of itraconazole, 300 mg/wk for 2 weeks of fluconazole, and 200 mg/d for 2 days of Pramiconazole. Contexte: Le pityriasis versicolor étendu ou récidivant peut se traiter par des antifongiques a ̀ action générale, mais aucun régime posologique n’a éte ́ approuve ́ pour cette indication. Objectif: L’étude visait a ̀ formuler des recommandations sur la posologie, fondées sur des données probantes. Méthode: Nous avons procéde ́ a ̀ un examen méthodique de la documentation a ̀ la recherche d’essais faisant état de la guériso
-
antifungal treatment for pityriasis versicolor
Journal of Fungi, 2015Co-Authors: Aditya K Gupta, Kelly A FoleyAbstract:Background: Pityriasis versicolor (PV), also known as tinea versicolor, is caused by Malassezia species. This condition is one of the most common superficial fungal infections worldwide, particularly in tropical climates. PV is difficult to cure and the chances for relapse or recurrent infections are high due to the presence of Malassezia in the normal skin flora. This review focuses on the clinical evidence supporting the efficacy of antifungal treatment for PV. Method: A systematic review of literature from the PubMed database was conducted up to 30 September 2014. The search criteria were "(pityriasis versicolor OR tinea versicolor) AND treatment", with full text available and English language required. Conclusions: Topical antifungal medications are the first-line treatment for PV, including zinc pyrithione, ketoconazole, and terbinafine. In cases of severe or recalcitrant PV, the oral antifungal medications itraconazole and fluconazole may be more appropriate, with Pramiconazole a possible future option. Oral terbinafine is not effective in treating PV and oral ketoconazole should no longer be prescribed. Maintenance, or prophylactic, therapy may be useful in preventing recurrent infection; however, at this time, there is limited research evaluating the efficacy of prophylactic antifungal treatment.
-
systematic review of systemic treatments for tinea versicolor and evidence based dosing regimen recommendations
Journal of Cutaneous Medicine and Surgery, 2014Co-Authors: Aditya K Gupta, Danielle Lane, Maryse PaquetAbstract:Background:Extensive or recurrent tinea versicolor (TV) can be treated with systemic antifungal therapies, but no dosing regimens have been approved for this indication.Objective:To provide evidence-based recommendations for dosing regimens.Methods:A systematic literature search was performed to identify trials reporting mycologic cure. All trials were included and assessed for quality. Correlation and statistical analyses were used to evaluate the effects of different dosing regimen parameters on efficacy.Results:Fifty-seven trials investigating itraconazole, ketoconazole, fluconazole, and Pramiconazole were included. Cumulative dose, treatment duration, and daily/weekly concentrations were shown to significantly influence mycologic cure rates for ketoconazole and Pramiconazole but not for itraconazole and fluconazole.Conclusion:Based on the efficacy evidence and potential safety concerns, this review supports the following dosing regimens: 200 mg/d for 5 or 7 days of itraconazole, 300 mg/wk for 2 weeks ...